drugset / Trial / NCT00116168
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase I studyto evaluate the safety and tolerability of escalating subcutaneous (SC) doses of MEDI-528 in to healthy adult volunteers.
Timeline
- Start
- 2005-06
- Primary completion
- 2006-04
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ENOKIZUMAB | Monoclonal antibody | 0.3 mg/kg | Subcutaneous |
| Subject | ENOKIZUMAB | Monoclonal antibody | 1 mg/kg | Subcutaneous |
| Subject | ENOKIZUMAB | Monoclonal antibody | 3 mg/kg | Subcutaneous |
| Subject | ENOKIZUMAB | Monoclonal antibody | 9 mg/kg | Subcutaneous |
Indications
No indication recorded.